Haixia Zhou

Haixia Zhou


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
YLYan-Yan Li
Yan-Yan Li
SGShuai-Shuai Ge
Shuai-Shuai Ge
YHYuan-Hong Huang
Yuan-Hong Huang
MXMing-Zhu Xu
Ming-Zhu Xu
CWChao-Ling Wan
Chao-Ling Wan
HDHaiping Dai
Haiping Dai

16 December 2023 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
XZXiuyan Zhang
Xiuyan Zhang
WMWenjuan Ma
Wenjuan Ma
WXWen Xue
Wen Xue
YWYu Wang
Yu Wang
PCPan Chen
Pan Chen
HZHaixia Zhou
Haixia Zhou
The formation of the BCR-ABL fusion gene drives human chronic myeloid leukemia (CML). The last 2 decades have witnessed that specific tyrosine kinase inhibitors (TKIs, e.g., imatinib mesylate, IM) against ABL1 improve disease treatment, although some patients still suffer from relapse and TKI resistance. Therefore, a better understanding of the molecular pathology of CML is still urgently needed. miR-181a-5p (miR-181a) acts as a tumor suppressor in CML; however, the molecular mechanism of miR-181a in CML stem/progenitor cells remains elusive. Herein, we showed that miR-181a inhibited the growth of CML CD34+ cells, including the quiescent subset, and sensitized them to IM treatment, while miR-181a inhibition by a sponge sequence collaborated with BCR-ABL to enhance the growth of normal CD34+ cells. Transcriptome data and biochemical analysis revealed that SERPINE1 was a bona fide and critical target of miR-181a, which deepened the understanding of the regulatory mechanism of SERPINE1. Genetic and pharmacological inhibition of SERPINE1 led to apoptosis mainly mediated by caspase-9 activation. The dual inhibition of SERPINE1 and BCR-ABL exhibited a significantly stronger inhibitory effect than a single agent. Taken together, this study demonstrates that a novel miR-181a/SERPINE1 axis modulates CML stem/progenitor cells, which likely provides an important approach to override TKI resistance.

5 September 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
DJDehuan Ji
Dehuan Ji
PZPengshan Zhang
Pengshan Zhang
WMWenjuan Ma
Wenjuan Ma
YFYiwen Fei
Yiwen Fei
WXWen Xue
Wen Xue
YZYun Zhao
Yun Zhao

1 July 2018 in Acta Biochimica et Biophysica Sinica
Verified
Journal Article
Closed access
PZPengshan Zhang
Pengshan Zhang
DJDehuan Ji
Dehuan Ji
XHXiaohui Hu
Xiaohui Hu
HNHengli Ni
Hengli Ni
WMWenjuan Ma
Wenjuan Ma
HZHaixia Zhou
Haixia Zhou
Heterogeneous nuclear ribonucleoproteins (hnRNPs) represent a large family of RNA-binding proteins. Heterogeneous nuclear ribonucleoprotein D-like (HNRPDL) is a member of this family. Though aberrant expression of HNRPDL has been reported in a few cancers, whether HNRPDL is deregulated in colon cancer patients and what role this protein plays in these cells are not known yet. In this study, we found that HNRPDL was significantly up-regulated in colon cancer specimens than control. We also demonstrated that HNRPDL silencing inhibited the growth of SW620 cells both in vitro and in vivo. Conversely, we constructed a retroviral vector to deliver HNRPDL into non-malignant NIH-3T3 cells and injected these cells into nude mice. HNRPDL-overexpressing NIH-3T3 cells generated tumors in nude mice but not the control cells. Mechanistically, HNRPDL promoted cell-cycle progression associated with enhanced expressions of cyclin D3 and Ki-67 but decreased expressions of p53 and p21. Taken together, our data demonstrate that HNRPDL is aberrantly expressed in colon cancer cells, which promotes the growth of these cells by activating cell-cycle progression.

20 October 2023 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
XZXiuyan Zhang
Xiuyan Zhang
YWYu Wang
Yu Wang
JLJinchang Lu
Jinchang Lu
LXLun Xiao
Lun Xiao
HCHui Chen
Hui Chen
YZYun Zhao
Yun Zhao
Background: Zinc finger protein X-linked (ZFX) has been shown to promote the growth of tumor cells, including leukemic cells. However, the role of ZFX in the growth and drug response of chronic myeloid leukemia (CML) stem/progenitor cells remains unclear. Methods: Real-time quantitative PCR (RT–qPCR) and immunofluorescence were used to analyze the expression of ZFX and WNT3 in CML CD34+ cells compared with normal control cells. Short hairpin RNAs (shRNAs) and clustered regularly interspaced short palindromic repeats/dead CRISPR-associated protein 9 (CRISPR/dCas9) technologies were used to study the role of ZFX in growth and drug response of CML cells. Microarray data were generated to compare ZFX-silenced CML CD34+ cells with their controls. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays were performed to study the molecular mechanisms of ZFX to regulate WNT3 expression. RT–qPCR and western blotting were used to study the effect of ZFX on β-catenin signaling. Results: We showed that ZFX expression was significantly higher in CML CD34+ cells than in control cells. Overexpression and gene silencing experiments indicated that ZFX promoted the in vitro growth of CML cells, conferred imatinib mesylate (IM) resistance to these cells, and enhanced BCR/ABL-induced malignant transformation. Microarray data and subsequent validation revealed that WNT3 transcription was conservatively regulated by ZFX. WNT3 was highly expressed in CML CD34+ cells, and WNT3 regulated the growth and IM response of these cells similarly to ZFX. Moreover, WNT3 overexpression partially rescued ZFX silencing-induced growth inhibition and IM hypersensitivity. ZFX silencing decreased WNT3/β-catenin signaling, including c-MYC and CCND1 expression. Conclusion: The present study identified a novel ZFX/WNT3 axis that modulates the growth and IM response of CML stem/progenitor cells.

27 October 2025 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
SXSheng-Li Xue
Sheng-Li Xue
MLMei-Jing Liu
Mei-Jing Liu
CQChong-Sheng Qian
Chong-Sheng Qian
SCSu-Ning Chen
Su-Ning Chen
HQHui-Ying Qiu
Hui-Ying Qiu
DWDepei Wu
Depei Wu